ImmunityBio Inc. Stock
€8.35
Your prediction
ImmunityBio Inc. Stock
Pros and Cons of ImmunityBio Inc. in the next few years
Pros
Cons
Performance of ImmunityBio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ImmunityBio Inc. | 0.140% | 55.717% | 52.861% | 154.473% | 377.183% | 223.023% | -68.763% |
| Biocryst Pharmaceuticals | 0.840% | 13.034% | 12.248% | -26.682% | -1.586% | -27.571% | -29.425% |
| Madrigal Pharmaceuticals inc. | -0.810% | -5.834% | -9.122% | 14.854% | -25.858% | 33.913% | 265.760% |
| Evolus Inc | -0.550% | 1.124% | -12.621% | -72.519% | -33.945% | -56.627% | -55.654% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of ImmunityBio, a company operating in the Biotechnology & Medical Research sector, the overall impression is that of a company grappling with significant challenges. Key metrics such as earnings, profitability, and valuation ratios suggest a period of struggle, which may be indicative of a firm still in the development stages of its products. This analysis aims to break down both the merits and downfalls of the current financial landscape to better understand ImmunityBio's potential trajectory.
Market Capitalization
Revenue Generation
Comments
News
Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700%
ImmunityBio (NASDAQ:IBRX), a developer of cancer and infectious-disease immunotherapies, closed Monday at $9.83, up 12.99%. The stock moved higher after earnings highlighted 700% ANKTIVA revenue
Why ImmunityBio Stock Is Soaring Again Today
Shares of cancer immunotherapy specialist ImmunityBio (NASDAQ: IBRX) are up 16% as of noon ET on Monday after the company reported fourth-quarter earnings. The company's leading immunotherapy (and
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer
ImmunityBio (NASDAQ:IBRX), which develops immunotherapies and vaccines for cancers and infectious diseases, closed Wednesday at $8.54, up 41.86%. The stock jumped after the European Commission